ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Understanding and Overcoming Antibody-Drug Conjugate Resistance: Biological Mechanisms and Emerging Analytical Frameworks in Breast Cancer.
Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Antibody-drug conjugates (ADCs) have revolutionized the treatment landscape of breast cancer by combining the precision of monoclonal antibodies with the potency of cytotoxic agents. Despite the clinical success of ADCs-with 4 FDA-approved agents to date, and 15 for the entire cancer landscape-their therapeutic durability is frequently undermined by acquired resistance. Rather than arising solely from tumor-intrinsic alterations, ADC resistance reflects a multi-layered process shaped by dynamic interactions among cancer cells and the tumor microenvironment (TME), with activation of adaptive signaling networks. For example, stromal architecture, vascular heterogeneity, and immune modulation intersect with clonal evolution, phenotypic plasticity, and pathway reprogramming, thereby constraining ADC delivery and activity. Cutting-edge technologies such as spatial omics, single-cell profiling, functional genomics, and patient-derived models are redefining how these resistance mechanisms are mapped and understood in situ. Building on these insights, emerging therapeutic strategies aim to overcome resistance through mechanism-guided interventions, including next-generation ADC designs, co-targeting of compensatory signaling pathways, and biomarker-informed therapeutic strategies. Together, these integrated biological and technological perspectives provide a framework for developing more durable and precisely tailored ADC-based therapies in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.